

Edgar Filing: ALKERMES INC - Form 8-K

ALKERMES INC
Form 8-K
December 08, 2003

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15 (d) of the
Securities Exchange Act of 1934

DATE OF REPORT - DECEMBER 8, 2003
(Date of earliest event reported)

ALKERMES, INC.
(Exact name of Registrant as specified in its charter)

PENNSYLVANIA	001-14131	23-2472830
(State of incorporation)	(Commission file number)	(IRS employer identification number)

88 SIDNEY STREET, CAMBRIDGE, MASSACHUSETTS 02139
(Address of principal executive offices, zip code)

AREA CODE (617) 494-0171
(Telephone number)

ITEM 5. OTHER INFORMATION.

Alkermes, Inc. announced preliminary results from its Phase III study of Vivitrex(R) (naltrexone for injectable suspension) in a total of 624 male and female patients with alcohol dependence. Patients received psychosocial therapy and once-monthly injections of Vivitrex 380 mg, Vivitrex 190 mg, or placebo for a six-month period. The primary endpoint of the study was the rate of heavy drinking over the period. In the overall study population, patients treated with Vivitrex 380 mg experienced approximately a 25% reduction in the rate of heavy drinking relative to placebo, which was statistically significant (p